MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.670
+0.290
+8.58%
After Hours: 3.690 +0.02 +0.55% 19:59 03/05 EST
OPEN
3.490
PREV CLOSE
3.380
HIGH
3.675
LOW
3.140
VOLUME
8.92M
TURNOVER
--
52 WEEK HIGH
6.25
52 WEEK LOW
0.8000
MARKET CAP
907.07M
P/E (TTM)
-14.1426
1D
5D
1M
3M
1Y
5Y
DJ MannKind Price Target Raised to $5.00/Share From $3.00 by SVB Leerink
Dow Jones · 2d ago
DJ MannKind Is Maintained at Outperform by SVB Leerink
Dow Jones · 2d ago
Analyst Actions: SVB Leerink Adjusts Price Target on MannKind to $5 From $3, Maintains Outperform Rating
MT Newswires · 2d ago
MannKind Corporation to Participate in H.C. Wainwright Global Life Sciences Conference
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced tod...
GlobeNewswire · 4d ago
MannKind prices upsized $200M convertible debt offering
MannKind (MNKD) prices $200M of 2.50% Convertible Senior Notes due 2026 (from $150M) in a private placement.Initial purchasers are granted an option to purchase up to an additional $30M of
Seekingalpha · 5d ago
BRIEF-Mannkind Corp Prices Upsized $200 Mln Convertible Senior Notes Offering
reuters.com · 5d ago
MannKind Corporation Prices Upsized $200.0 Million Convertible Senior Notes Offering
WESTLAKE VILLAGE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the pricing of $200.0 million aggregate principal amount of 2.50% Convertible Senior Notes due 2026 (the "notes") in a private placement (the "...
GlobeNewswire · 5d ago
MannKind Prices Upsized Private Placement of $200 Million Convertible Senior Notes
MT Newswires · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MNKD. Analyze the recent business situations of MannKind through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MNKD stock price target is 6.60 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 235
Institutional Holdings: 80.89M
% Owned: 32.73%
Shares Outstanding: 247.16M
TypeInstitutionsShares
Increased
53
9.49M
New
49
1.14M
Decreased
36
4.35M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
James Shannon
Chief Executive Officer/Director
Michael Castagna
Chief Financial Officer
Steven Binder
Chief Human Resource Officer
Stuart Tross
Executive Vice President/General Counsel/Secretary
David Thomson
Chief Technology Officer
Joseph Kocinsky
Vice President/Controller/Treasurer/Director of Investor Relations
Rosabel Alinaya
Other
Patrick McCauley
Vice President
Kevin Kaiserman
Director
Sabrina Kay
Director
Kent Kresa
Independent Director
Ronald Consiglio
Independent Director
Michael Friedman
Independent Director
Jennifer Grancio
Independent Director
David Maccallum
Independent Director
Anthony Hooper
Independent Director
Christine Mundkur
No Data
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company's product candidate is Afrezza (insulin human) Inhalation Powder, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its technosphere formulation technology. The technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics.

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.